Literature DB >> 1315283

Targeting of poly(rI)-poly(rC) by fusogenic (F protein) immunoliposomes.

B Compagnon1, P Milhaud, A Bienvenüe, J R Philippot.   

Abstract

The aim of this study is to investigate the intracellular delivery of polynucleotides by fusogenic immunoliposomes. We have studied the internalization of poly(rI)-poly(rC) (polyIC) by liposomes into murine L929 cells. The liposomes were prepared by incorporating Sendaï virus fusogenic F protein into the lipid bilayer and targeted by a monoclonal antibody (mAb) bound to the liposomes via protein A (Staphylococcus aureus). The immunoliposomes ensured a sufficient yield of polyIC internalization, which was estimated by its ability to induce antiviral activity. In the absence of RNase treatment free and encapsulated polyIC had the same inducing effect, but in the presence of nuclease only the encapsulated polyIC, and not free polyIC, maintained its antiviral effect. The fusion process making possible the internalization of polyIC was confirmed by the fact that the polyIC effect was mainly inhibited by an anti-F protein mAb which inhibited erythrocyte hemolysis by the virus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315283     DOI: 10.1016/0014-4827(92)90180-g

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

1.  Cellular delivery of oligonucleotides by synthetic import peptide carrier.

Authors:  S Dokka; D Toledo-Velasquez; X Shi; L Wang; Y Rojanasakul
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

2.  Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide.

Authors:  J P Bongartz; A M Aubertin; P G Milhaud; B Lebleu
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

3.  Development of Drugs Based on High-Polymeric Double-Stranded RNA for Antiviral and Antitumor Therapy.

Authors:  E D Danilenko; A O Belkina; G M Sysoeva
Journal:  Biochem Mosc Suppl B Biomed Chem       Date:  2019-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.